M&A Deal Summary |
|
---|---|
Date | 2010-10-08 |
Target | Cypress Bioscience - Diagnostic Business |
Sector | Life Science |
Buyer(s) | Exagen |
Sellers(s) | Cypress Bioscience |
Deal Type | Divestiture |
Deal Value | 8M USD |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 2002 |
Sector | Life Science |
Employees | 174 |
Revenue | 53M USD (2023) |
Exagen is a patient-focused, discovery-driven, CLIA-certified, CAP-accredited laboratory focused on providing physicians with products that address the significant unmet need for accurate and timely diagnosis, prognosis and monitoring of ARD/CTD. Exagen was founded in 2002 and is based in Vista, California.
DEAL STATS | # |
---|---|
Overall | 1 of 1 |
Sector (Life Science) | 1 of 1 |
Type (Divestiture) | 1 of 1 |
State (California) | 1 of 1 |
Country (United States) | 1 of 1 |
Year (2010) | 1 of 1 |
Size (of disclosed) | 1 of 1 |
Cypress Bioscience, Inc. is committed to developing and commercializing pharmaceutical products and personalized medicine laboratory services that allow physicians to serve unmet medical needs.
DEAL STATS | # |
---|---|
Overall | 1 of 1 |
Sector (Life Science) | 1 of 1 |
Type (Divestiture) | 1 of 1 |
State (California) | 1 of 1 |
Country (United States) | 1 of 1 |
Year (2010) | 1 of 1 |
Size (of disclosed) | 1 of 1 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2008-02-25 |
Proprius Pharmaceuticals
San Diego, California, United States Proprius Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and markets personalized medicine solutions in rheumatology and autoimmune diseases. |
Buy | $38M |